Stock Analysis
Bruker Corporation (BRKR) Stock Analysis
Bruker Corporation (BRKR) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Bruker Corporation (BRKR) currently has an AIQ Score of 64/100, indicating a neutral setup. Momentum is the strongest factor at 83/100. Risk is the weakest current factor at 44/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
BRKR at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $63.26 |
| AIQ Score | 64/100 |
| Overall View | Neutral |
| Technical Analysis Consensus | Strong Buy |
| Market Cap | $9.39B |
| P/E Ratio (TTM) | -55.83 |
| Forward P/E | — |
| EPS (Q3 FY2026) | -$0.81 |
| Revenue (Q3 FY2026) | $874M |
| Dividend Yield (TTM) | 0.33% |
| Beta | 1.73 |
| Volume | 1.73M |
| 52-week range | $32.37-$68.98 |
| RSI 14 | 52.52 |
| 50-Day SMA | $59.48 |
| 200-Day SMA | $50.82 |
| Analyst Price Target | $71.67 |
| Next Earnings | Feb 11, 2027 |
BRKRBruker Corporation
Healthcare / Medical - Devices
Low Priority
Above Peers
Latest quote
- Momentum83
- Value53
- Quality60
- Risk resilience44
- Sentiment—
BRKR Stock Analysis Summary
Bruker Corporation (BRKR) currently has an AIQ Score of 64/100, indicating a neutral setup. Momentum is the strongest factor at 83/100. Risk resilience is the weakest current factor at 44/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a neutral regime, BRKR has AIQ Score of 64/100 with Momentum base of 83/100 and fading Risk resilience at 44/100. Wait for component alignment before adding exposure.
Momentum (83/100) leads while Risk resilience (44/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · 3.10% stock move · BRKR classified in Medical - Devices.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is BRKR Bullish or Bearish Right Now?
BRKR currently has a neutral overall setup. Momentum is the strongest factor at 83/100, while Risk Resilience is weakest at 44/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.
- - Momentum is constructive at 83/100.
- - Price is +3.54% above its 50-day SMA.
- - Analyst target implies +13.29% upside from the latest quote.
- - Technical consensus has more buy votes than sell votes (31 vs 5).
- - Risk Resilience is weak at 44/100.
Current Consensus
BRKR's Technical Analysis Consensus is currently Strong Buy, with 31 buy, 10 neutral, and 5 sell votes. BRKR's 14-day RSI is 52.52, which places the stock in a neutral momentum range. BRKR's beta is 1.73, indicating greater market sensitivity than the broad market.
What Changed in BRKR?
The largest recent change in BRKR is Value moving down by 2.0 points over the available 7-day comparison window. Momentum remains the strongest visible factor.
What Would Change the BRKR Outlook?
The current neutral outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
BRKR Decision Framework
Public evidence layers, setup checks, and risk context for Bruker Corporation.
Bruker Corporation (BRKR) Stock Analysis
Bruker Corporation has an AIQ Score of 64/100 in a Neutral regime. Momentum is strongest at 83/100. Beta is 1.73, above market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | BRKR is in a Neutral AIQ regime with score 64/100. |
| Signal Conflict | The primary conflict is that momentum leads at 83/100 while risk lags at 44/100. |
| Factor Evidence | Momentum 83/100 · Value 53/100 · Quality 60/100 · Risk 44/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Momentum is the strongest factor at 83/100.
Momentum is 83/100 and RSI (14) is 52.5.
BRKR is in a Neutral regime at 64/100.
Risk factor is 44/100 with beta 1.73 and annual volatility 59.79%.
Current conflict: momentum leads at 83/100 while risk lags at 44/100.
BRKR Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
BRKR Fundamentals
BRKR valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
BRKR Technical Analysis
BRKR technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
BRKR Stock Catalysts
Track BRKR earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
BRKR Dividend Analysis
BRKR dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
BRKR Financial Data
BRKR revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
BRKR Risk Analysis
BRKR volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
BRKR Stock News
BRKR stock news, market tone, recent headlines, and catalyst context.
BRKR vs Medical - Devices Peers
Current peer cohort: BRKR · CNMD · ESTA · GKOS · HAE. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| BRKR Current stock | 64/100 | 53/100 | 83/100 | 44/100 | 0.89 | 59.79% | Current |
| CNMD CONMED Corporation | 71/100 | 84/100 | 74/100 | 58/100 | 0.48 | 46.99% | BRKR vs CNMD |
| ESTA Establishment Labs Holdings Inc. | 48/100 | 32/100 | 58/100 | 47/100 | 0.35 | 49.89% | BRKR vs ESTA |
| GKOS Glaukos Corporation | 65/100 | 30/100 | 90/100 | 57/100 | 1.83 | 61.36% | BRKR vs GKOS |
| HAE Haemonetics Corporation | 77/100 | 60/100 | 91/100 | 67/100 | 1.35 | 41.04% | BRKR vs HAE |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 18, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
Also for BRKR: historical return with reinvested dividends, dollar-cost averaging (DCA) backtest and stock average calculator for several buys.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Nov 19, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Sep 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching BRKR
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for BRKR
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
BRKR Stock FAQ
What is BRKR stock price today?
Bruker Corporation's current stock price is $63.26. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is BRKR bullish or bearish right now?
BRKR's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is BRKR's market cap?
BRKR's market cap is $9.39B based on the latest completed market-close snapshot from Nov 18, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is BRKR's current P/E ratio?
BRKR's current P/E ratio is -55.83 based on the latest completed market-close snapshot from Nov 18, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is BRKR's RSI?
BRKR's 14-day RSI is 52.52 based on the latest completed market-close snapshot from Nov 18, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is BRKR above its 50-day and 200-day moving averages?
BRKR is 3.54% from its 50-day SMA and 21.20% from its 200-day SMA based on the latest completed market-close snapshot from Nov 18, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is BRKR's next earnings date?
BRKR's next earnings date is currently listed as Feb 11, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does BRKR pay a dividend?
BRKR's dividend yield is 0.33% based on the latest completed market-close snapshot from Nov 18, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.